Nurse Practitioner, Family · Las Cruces, NM
NPI
1538671078
Since 2017
Specialty
Nurse Practitioner, Family
Code 363LF0000X
Group practices
3
Medicare group memberships
Hospitals
1
Hospital affiliations
4672 N Sonoma Ranch Blvd Ste B
Las Cruces, NM, 88011
Phone (575) 556-1879
Groups this clinician bills Medicare through
Medicare paid, 2024
$113K
1,971 services
Medicare patients, 2024
440
Average age 74
Drug cost, 2024
$127K
2,274 prescriptions
Company payments, 2025
$87.73
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Matthew R Arenibas was code 99309 (snf e&m), 585 times for 62 patients. In total Matthew R Arenibas billed 1,971 services in 58 codes, and Medicare paid $113K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-08-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99309 SNF E&M | Facility | 585 | 62 | $71.39 | $42K |
| 99310 SNF E&M | Facility | 267 | 56 | $105.99 | $28K |
| 99214 Office E&M - Established | Office | 200 | 178 | $69.16 | $14K |
| 99213 Office E&M - Established | Office | 192 | 177 | $48.96 | $9,400 |
| 87880 Immunoassay | Office | 150 | 134 | $16.09 | $2,414 |
| 87426 Immunoassay | Office | 133 | 122 | $34.62 | $4,604 |
| 81003 Clinical Chemistry | Office | 83 | 72 | $2.17 | $180 |
| 87804 Immunoassay | Office | 59 | 59 | $16.22 | $957 |
| 87636 Infectious Agent Detection by DNA/RNA | Office | 41 | 40 | $139.78 | $5,731 |
| 36415 Venipuncture Blood Collection | Office | 34 | 30 | $8.65 | $294 |
| 96372 Injection Administration | Office | 26 | 26 | $6.41 | $167 |
| 87807 Immunoassay | Office | 21 | 21 | $12.84 | $270 |
| 71046 X-ray - Chest | Office | 17 | 17 | $15.23 | $259 |
| 99306 SNF E&M | Facility | 14 | 14 | $127.23 | $1,781 |
By year: 2022 $28K for 818 services; 2023 $63K for 1,408 services; 2024 $113K for 1,971 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 87880 Immunoassay | 150 | 134 | $16.09 | $2,414 |
| 87426 Immunoassay | 133 | 122 | $34.62 | $4,604 |
| 81003 Clinical Chemistry | 83 | 72 | $2.17 | $180 |
| 87804 Immunoassay | 59 | 59 | $16.22 | $957 |
| 87636 Infectious Agent Detection by DNA/RNA | 41 | 40 | $139.78 | $5,731 |
| 36415 Venipuncture Blood Collection | 34 | 30 | $8.65 | $294 |
| 87807 Immunoassay | 21 | 21 | $12.84 | $270 |
Medicare prescription drug claims, 2024
In 2024, the drug Matthew R Arenibas prescribed most often to Medicare patients was Amoxicillin-Clavulanate Potass (Amoxicillin/Potassium Clav), with 86 prescriptions and refills. In total Matthew R Arenibas wrote 2,274 Medicare prescriptions that cost $127K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | 86 | 86 | 77 | $992 |
| Ibuprofen Generic | 80 | 80 | 77 | $482 |
| Fluticasone Propionate Generic | 77 | 104 | 70 | $1,083 |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | 73 | 73 | 54 | $1,127 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 57 | 57 | 39 | $442 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 54 | 54 | Under 11 | $1,323 |
| Azithromycin Generic | 54 | 54 | 50 | $255 |
| Cephalexin Generic | 51 | 51 | 45 | $716 |
| Lagevrio (Eua) Molnupiravir | 51 | 51 | 48 | $38K |
| Prednisone Generic | 47 | 47 | 44 | $108 |
| Furosemide Generic | 45 | 45 | 12 | $316 |
| Hydroxyzine Hcl Generic | 45 | 45 | 17 | $828 |
| Levothyroxine Sodium Generic | 43 | 43 | Under 11 | $512 |
| Atorvastatin Calcium Generic | 43 | 43 | 13 | $696 |
| Pantoprazole Sodium Generic | 42 | 42 | 13 | $682 |
Brand drugs: 327 claims; generic drugs: 1,891 claims; opioid claims: 94.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Matthew R Arenibas $87.73 ($87.73 in general payments such as food, travel and fees) from 3 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $47.31.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.